BPC-157 (Body Protective Compound-157) is a synthetic 15-residue peptide derived from a protective protein found in human gastric juice. It is widely studied in preclinical animal models for tendon, ligament, gut, and soft-tissue repair.

Is BPC-157 FDA-approved?

No. BPC-157 is not approved by the FDA, MHRA, Health Canada, or the TGA for human use. Research-peptide vendors sell it for laboratory research only.

What is the half-life of BPC-157?

Published pharmacokinetic studies report a systemic plasma half-life under 30 minutes after IV or IM administration in rodent models. Local tissue effects appear to persist substantially longer than the circulating half-life would suggest.

What dose of BPC-157 is used in research?

Doses reported in published preclinical studies vary by route, model, and target tissue. Pepticker does not publish a recommended dosing protocol — refer to the peer-reviewed literature for the specific study you are reproducing.

What is BPC-157 commonly stacked with?

In published research and vendor protocols, BPC-157 is most often paired with TB-500 for soft-tissue work, KPV for gastrointestinal protocols, and GHK-Cu for skin and connective-tissue research.

BPC-157 is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

healing

BPC-157

Tissue-repair research peptide

0 vendors tracked0 live pricesLast crawl: warming up

About

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice. Widely studied in preclinical models for tendon, ligament, and gastrointestinal tissue recovery.

Also known as: Body Protective Compound-157

Commonly cited research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Range10 – 500 mcg

Study type: Preclinical rodent models and a pharmacokinetics/safety evaluation in rats and dogs.

Literature notes: Literature reports subcutaneous and intraperitoneal administration in rodent models; human pharmacokinetic data are limited to a single-dose safety study.

Citations

Xu et al., Regul Toxicol Pharmacol, 2020
“BPC-157 was well tolerated across species with no dose-limiting toxicity observed.”
Chang et al., Front Pharmacol, 2022 (PK/ADME study)
“Pharmacokinetic parameters were characterized following single intravenous and intramuscular administrations in rats.”
Sikiric et al., Pharmaceuticals, 2025

Last verified: May 3, 2026

Reconstitution calculator

For research purposes only. Not for human consumption. Always verify calculations independently.

VialPeptide mass in vial (mg)mgBacteriostatic water added (mL)mL

DoseDesired dose

Syringe

How reconstitution works · Understanding syringe units

Cost-per-dose recalculates as you adjust the calculator above.

§ Frequently asked

Common questions about BPC-157

What is BPC-157?: BPC-157 (Body Protective Compound-157) is a synthetic 15-residue peptide derived from a protective protein found in human gastric juice. It is widely studied in preclinical animal models for tendon, ligament, gut, and soft-tissue repair.
Is BPC-157 FDA-approved?: No. BPC-157 is not approved by the FDA, MHRA, Health Canada, or the TGA for human use. Research-peptide vendors sell it for laboratory research only.
What is the half-life of BPC-157?: Published pharmacokinetic studies report a systemic plasma half-life under 30 minutes after IV or IM administration in rodent models. Local tissue effects appear to persist substantially longer than the circulating half-life would suggest.
What dose of BPC-157 is used in research?: Doses reported in published preclinical studies vary by route, model, and target tissue. Pepticker does not publish a recommended dosing protocol — refer to the peer-reviewed literature for the specific study you are reproducing.
What is BPC-157 commonly stacked with?: In published research and vendor protocols, BPC-157 is most often paired with TB-500 for soft-tissue work, KPV for gastrointestinal protocols, and GHK-Cu for skin and connective-tissue research.
Is BPC-157 legal?: BPC-157 is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.

Research use only. The compounds listed on this page are not approved for human use through research-chemical channels. Nothing on this page is medical advice. Consult a qualified clinician before considering any peptide protocol. See affiliate disclosure and our scoring methodology.

Keep exploring

Common questions about BPC-157

More on BPC-157 & related research